INOVIO PHARMACEUTICALS INC (INO) Stock Price, Quote, News and Overview
NASDAQ:INO - Nasdaq - US45773H4092 - Common Stock - Currency: USD
INO Quote, Performance and Key Statistics
2.24
+0.02 (+0.9%)
The current stock price of INO is 2.24 USD. In the past month the price decreased by -2.18%. In the past year, price decreased by -71.56%.
INO Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About INO
Company Profile
Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. The company is headquartered in San Diego, California and currently employs 122 full-time employees. The firm is focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines pipeline include INO-3107 for HPV-related recurrent respiratory papillomatosis (RRP); INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, or OPSCC; VGX-3100 for the treatment of Anal or Perianal HSIL; INO-5401 for the treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Treatment of Glioblastoma Multiforme (GBM). Its lead candidate is INO-3107 for the treatment of RRP, a rare and debilitating disease of the respiratory tract caused by HPV infection. Its DNA medicines platform consists of DNA plasmids and its CELLECTRA devices, which are used to deliver the DNA plasmids into the cell. Its CELLECTRA device portfolio consists of two models.
Company Info
INOVIO PHARMACEUTICALS INC
6769 Mesa Ridge Rd.
San Diego CALIFORNIA 19462 US
CEO: J. Joseph Kim
Employees: 127
Company Website: https://www.inovio.com/
Investor Relations: https://ir.inovio.com
Phone: 18584103134
INOVIO PHARMACEUTICALS INC / INO FAQ
What is the stock price of INOVIO PHARMACEUTICALS INC today?
The current stock price of INO is 2.24 USD. The price increased by 0.9% in the last trading session.
What is the ticker symbol for INOVIO PHARMACEUTICALS INC stock?
The exchange symbol of INOVIO PHARMACEUTICALS INC is INO and it is listed on the Nasdaq exchange.
On which exchange is INO stock listed?
INO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for INOVIO PHARMACEUTICALS INC stock?
10 analysts have analysed INO and the average price target is 9.69 USD. This implies a price increase of 332.59% is expected in the next year compared to the current price of 2.24. Check the INOVIO PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is INOVIO PHARMACEUTICALS INC worth?
INOVIO PHARMACEUTICALS INC (INO) has a market capitalization of 80.75M USD. This makes INO a Micro Cap stock.
How many employees does INOVIO PHARMACEUTICALS INC have?
INOVIO PHARMACEUTICALS INC (INO) currently has 127 employees.
What are the support and resistance levels for INOVIO PHARMACEUTICALS INC (INO) stock?
INOVIO PHARMACEUTICALS INC (INO) has a support level at 1.95 and a resistance level at 2.3. Check the full technical report for a detailed analysis of INO support and resistance levels.
Is INOVIO PHARMACEUTICALS INC (INO) expected to grow?
The Revenue of INOVIO PHARMACEUTICALS INC (INO) is expected to decline by -88.18% in the next year. Check the estimates tab for more information on the INO EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy INOVIO PHARMACEUTICALS INC (INO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of INO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of INO, evaluating the profitability, health, valuation and growth aspects
- INOVIO PHARMACEUTICALS INC (INO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- INOVIO PHARMACEUTICALS INC (INO) Sales and EPS estimates to see what analysts future expectations are.
- INOVIO PHARMACEUTICALS INC (INO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- INOVIO PHARMACEUTICALS INC (INO) Insider and Institutional Ownership to learn about the owners and their transactions.
- INOVIO PHARMACEUTICALS INC (INO) Stock Chart to make your own analysis
- INOVIO PHARMACEUTICALS INC (INO) Latest news and press-releases to stay up to date.
Does INOVIO PHARMACEUTICALS INC (INO) stock pay dividends?
INO does not pay a dividend.
When does INOVIO PHARMACEUTICALS INC (INO) report earnings?
INOVIO PHARMACEUTICALS INC (INO) will report earnings on 2025-03-04, after the market close.
What is the Price/Earnings (PE) ratio of INOVIO PHARMACEUTICALS INC (INO)?
INOVIO PHARMACEUTICALS INC (INO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.51).
What is the Short Interest ratio of INOVIO PHARMACEUTICALS INC (INO) stock?
The outstanding short interest for INOVIO PHARMACEUTICALS INC (INO) is 14.17% of its float. Check the ownership tab for more information on the INO short interest.
INO Technical Analysis
INO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to INO. The financial health of INO is average, but there are quite some concerns on its profitability.
INO Financial Highlights
Over the last trailing twelve months INO reported a non-GAAP Earnings per Share(EPS) of -4.51. The EPS increased by 40.34% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -105.43% | ||
| ROE | -153.49% | ||
| Debt/Equity | 0 |
INO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 78% to INO. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of 31% and a revenue growth -88.18% for INO